Related Experiment Video
Updated: May 18, 2026
An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
Published on: December 3, 2020
Development and validation of an enzyme-linked immunosorbent assay for the quantification of cytochrome 3A4 in human
Lies De Bock1, Pieter Colin, Koen Boussery
1Laboratory of Medical Biochemistry and Clinical Analysis, Ghent University, Harelbekestraat 72, 9000 Gent, Belgium. Lies.DeBock@UGent.be
Insights
This study developed an ELISA to quantify CYP3A4 in pediatric liver microsomes, crucial for understanding drug metabolism in children with liver disease. The assay provides accurate and precise measurements, aiding future research on pediatric drug efficacy and safety.
Area of Science:
- Pharmacology
- Biochemistry
- Pediatric Medicine
Background:
- Hepatic pathologies can alter cytochrome P450 (CYP) mediated drug metabolism in children.
- Accurate quantification of CYP isoforms in pediatric microsomes is needed to understand these changes.
- Western blotting offers only semi-quantitative data for CYP abundance.
Purpose of the Study:
- Develop and validate an indirect ELISA for quantifying CYP3A4 in human liver microsomes.
- Establish a reliable method for measuring CYP3A4 abundance in pediatric samples.
- Improve the understanding of drug metabolism in pediatric liver disease.
Main Methods:
- Developed an indirect ELISA using a polyclonal antibody against human CYP3A4.
- Validated the assay for sensitivity, working range, accuracy, and precision.
- Used commercially available reagents and a 5-parameter logistics function for quantification.
Main Results:
- The ELISA accurately quantified CYP3A4 from 2 to 300 pmol/mg microsomal protein.
- Intra-assay and inter-assay coefficients of variation were below 15% (except at LLOQ).
- Relative and total error analyses confirmed the assay's accuracy and precision, with minimal cross-reactivity with CYP2E1.
Conclusions:
- The developed ELISA is a sensitive and accurate method for quantifying CYP3A4 in human liver microsomes.
- This assay is valuable for studying drug metabolism in pediatric populations, especially those with hepatic pathologies.
- The method's successful application in an ongoing study highlights its utility in clinical research.
Abstract:
Little is known about the influence of hepatic pathologies on cytochrome P450 (CYP) mediated drug metabolism in children. The determination of the abundance of the different isoforms in pediatric microsomes may provide valuable information on the mechanisms of possible changes in activity. Until now, western blotting was mostly used for abundance measurements, but this technique only provides semi-quantitative data. Therefore, this study aimed to develop and validate an indirect ELISA for the quantification of the most important CYP isoform, CYP3A4, in human liver microsomes, using commercially available reagents. Samples, calibrators and validation samples were diluted to a final concentration of 10 μg microsomal protein/ml. A polyclonal antibody raised against the full length human protein was used as primary antibody; horseradish peroxidase conjugated secondary antibodies for detection. The assay was validated for sensitivity, working range and calibration, accuracy and precision. Amounts of CYP3A4 between 2 and 300 pmol/mg microsomal protein could be quantified with a 5-parameter logistics function with 1/x weighting factor. Coefficients of variation of intra and inter assay variability were between 9.54 and 13.98% (16.34% at LLOQ), and between 10.51 and 14.55% (19.44% at LLOQ), respectively. The relative error (%RE) varied between -5.96 and 6.68% (11.53% at LLOQ), and the total error between 11.93 and 21.23% (30.97% at LLOQ). The cross-reactivity of the method with human CYP2E1 showed to have no significant effect on the accuracy of the results. Successful analysis of five samples from an ongoing study demonstrated the usefulness of the method.
